Biotechnology & Life Sciences M&A Transactions

Cohere strengthens its enterprise AI platform with Reliant AI acquisition, boosting capabilities in secure biopharma and healthcare solutions.

SERB Pharmaceuticals secures European and MENA rights for Hansa Biopharma's Idefirix® (imlifidase) in a €115M deal, enhancing kidney transplant options.

SERB Pharmaceuticals secures European and MENA rights for Hansa Biopharma's imlifidase, a key therapy for highly sensitized kidney transplant patients, in a €115M deal.

Cohere strengthens its healthcare AI capabilities by acquiring Reliant AI, integrating specialized biomedical data and expertise into its enterprise platform.

Cohere strengthens its biopharma AI capabilities by acquiring Reliant AI, integrating advanced technology for drug discovery and R&D. Learn more.

Neurocrine Biosciences strengthens rare disease portfolio with $2.9B acquisition of Soleno Therapeutics and its PWS treatment, VYKAT XR.

EQT AB and IDG Capital are shortlisted to acquire Swiss peptide drug manufacturer PolyPeptide Group, valued at $1.6 billion. Altaris also remains in talks.

Cumming Group enhances its Advanced Technologies division with the acquisition of RGD Project Management, boosting its capabilities in the US life sciences manufacturing sector.

OrganaBio secures Excellos' assets, establishing a bicoastal cell therapy CDMO to address critical manufacturing and supply chain needs.

Cellular Intelligence

Cellular Intelligence acquires Parkinson's cell therapy rights from Novo Nordisk, leveraging AI for faster development and manufacturing. Backed by Khosla Ventures, CZI, SciFi VC, AMD Ventures.

Eli Lilly's $3.25B acquisition of Kelonia Therapeutics bolsters its oncology pipeline with advanced CAR-T technology. Learn about this strategic biotech deal.

BioPhorum enhances its implementation services by acquiring PharmaX Solutions, boosting digital transformation and operational efficiency in the life sciences sector.

Bayer's $2.45B acquisition of Perfuse Therapeutics bolsters its ophthalmology pipeline with a novel treatment for glaucoma and diabetic retinopathy.

Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1B, significantly expanding its U.S. rare disease and neurological disorder footprint.

Merck strengthens its oncology pipeline by acquiring Terns Pharmaceuticals for $5.8 billion, adding a promising CML treatment candidate.